Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study.

2014-08-14

Simpson, Richard W

Nicholson, Geoffrey C

Proietto, Joseph

Sarah, Alana

Sanders, Kerrie M

Phillips, Gabrielle

Chambers, Jo

MacGinley, Rob

Orford, Neil

Walder, Ken

Krippner, Guy

Skoff, Kathy

Wacher, Vincent J

Journal Article

10.2337/dc14-1038

To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes.This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point for methazolamide treatment was a placebo-corrected reduction in HbA1c from baseline after 24 weeks (ΔHbA1c).Mean ± SD baseline HbA1c was 7.1 ± 0.7% (54 ± 5 mmol/mol; n = 37) and 7.4 ± 0.6% (57 ± 5 mmol/mol; n = 39) in the methazolamide and placebo groups, respectively. Methazolamide treatment was associated with a ΔHbA1c of -0.39% (95% CI -0.82, 0.04; P < 0.05) (-4.3 mmol/mol [-9.0, 0.4]), an increase in the proportion of patients achieving HbA1c ≤6.5% (48 mmol/mol) from 8 to 33%, a rapid reduction in alanine aminotransferase (∼10 units/L), and weight loss (2%) in metformin-cotreated patients.Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control.

link

Diabetes Care 2014; 37(11): 3121-3

Diabetes Care